Drug to treat agitation in Alzheimer’s patients approved in Canada – National
Health Canada has green lit a drug previously approved for schizophrenia and depression to treat symptoms of agitation in Alzheimer’s patients. Rexulti (brexpiprazole) oral tablets manufactured by Otsuka Pharmaceutical Canada Inc. and Lundbeck Canada Inc. were issued a Notice of Compliance by the regulator, according to a company release Wednesday. This approval was given after … Read more
